In androgen-independent prostate cancer cells, Runx2 modulates EMT by switching of E-cadherin to N-cadherin and FTY720 down-regulated Runx2 thereby reversing the cadherin switch 76. The gene discussed is RUNX2; the disease is prostate carcinoma.